SR One, the independent venture arm of London-based drug giant GlaxoSmithKline (NYSE:GSK), has established a San Francisco office after a long history of backing West Coast biotechs such as Amgen (NASDAQ:AMGN) and Idec Pharmaceuticals (now part of Biogen Idec (NASDAQ:BIIB) of Weston, MA), the group announced today. Simeon George, a partner at SR One, is leading the venture group’s San Francisco office. SR One now has offices in London, Boston, Philadelphia, and San Francisco. Christoph Westphal, the president of SR One, is expected to leave his post at SR One later this year and is now a partner and founder at Boston-based venture firm Longwood Founders Fund.
By posting a comment, you agree to our terms and conditions.